Skip to main content

Table 2 Clinical evolution (maximum or minimum values) of the original-eligible population and weighted population while treated with HFNO

From: Awake prone positioning does not reduce the risk of intubation in COVID-19 treated with high-flow nasal oxygen therapy: a multicenter, adjusted cohort study

°

Original sample

Weighted sample

HFNO (n = 133)

HFNO + awake-PP (n = 51)

P value

HFNO 68.4%

HFNO + awake-PP 31.6%

P value

Scores

 Non-respiratory SOFA

4.0 [4.00–5.00]/125

4.0 [4.00–5.00]/46

0.25

4.8

5.0

0.62

Vital signs

 Temperature, °C

37.2 [36.50–38.00]/141

37.1 [36.60–37.80]/54

0.80

37.2

37.3

0.53

 Mean arterial pressure, mmHg

77.0 [70.50–83.83]/140

76.2 [68.00–84.00]/54

0.59

77.8

73.4

0.053

 Heart rate, bpm

85.0 [75.00–96.00]/141

85.0 [79.00–100.00]/54

0.62

87.2

91.4

0.26

 SpO2, %

89.0 [86.00–92.00]/141

88.0 [84.00–90.00]/54

0.11

88.8

87.6

0.21

 Respiratory rate minimum, bpm

21.0 [18.00–24.00]/141

19.0 [16.00–23.00]/54

0.004

20.8

19.7

0.23

 Respiratory rate maximum, bpm

27.0 [24.00–32.00]/141

27.0 [23.00–30.00]/54

0.49

27.7

27.1

0.64

Arterial blood gas

 PaO2/FiO2

92.5 [77.00–125.50]/128

103.0 [80.00–125.00]/53

0.45

109.7

113.8

0.67

 PaCO2, mmHg

39.9 [35.50–48.00]/131

41.2 [36.20–46.00]/53

0.56

44.8

42.4

0.29

Laboratory findings

 Ferritin, ng/mL

1279.0 [694.00–2151.00]/107

1499.0 [809.00–2425.00]/45

0.45

1817.2

1955.0

0.75

 D-Dimer, ng/mL

1681.0 [820.00–4200.00]/122

1590.0 [1030.00–3200.00]/50

0.98

2799.7

2624.9

0.76

 CRP, mg/dL

21.3 [9.32–33.19]/132

22.7 [8.66–146.14]/53

0.23

62.4

62.6

0.98

 Lymphocytes, μL

0.47 [0.30–0.74]/135

0.44 [0.30–0.60]/53

0.31

0.56

0.42

0.021

 IL-6, pg/mL

177.0 [42.70–415.90]/17

87.5 [24.00–301.00]/14

0.34

832.7

221.6

0.33

 LDH, U/L

429.0 [345.00–561.00]/125

449.0 [352.00–602.00]/51

0.51

451.2

490.3

0.29

 Leukocytes, 103/μL

8.3 [5.80–12.00]/122

7.7 [5.21–12.33]/51

0.75

9.7

9.0

0.60

 Procalcitonin, ng/mL

0.22 [0.11–0.57]/114

0.20 [0.09–0.34]/45

0.57

1.24

0.34

0.10

 Platelets, 1000/mm3

319.0 [212.50–410.50]/136

303.0 [244.00–358.00]/53

0.64

330.6

329.7

0.97

 Bilirrubin, mg/dL

0.80 [0.50–1.10]/130

0.84 [0.60–1.18]/50

0.33

1.23

0.90

0.052

 ALT, U/L

66.0 [30.00–104.00]/135

52.0 [32.00–116.00]/53

0.82

85.2

105.6

0.35

 Creatinin, mg/dL

0.90 [0.70–1.18]/136

0.86 [0.75–1.02]/52

0.45

1.10

1.09

0.96

 Urea, mg/dL

42.0 [30.00–64.00]/91

39.5 [26.00–61.00]/50

0.44

52.0

42.7

0.12

 Troponin, ng/mL

11.8 [4.30–25.00]/89

9.6 [4.60–27.52]/39

0.69

18.8

9.3

0.27

 NTproBNP, pg/mL

335.5 [125.50–938.80]/20

303.1 [91.00–1019.00]/14

0.75

727.9

660.9

0.82

 Hematocrit, %

38.00 [34.70–42.00]/111

39.20 [36.00–42.50]/45

0.97

38.2

39.4

0.35

 Lactate, mmol/L

1.5 [1.16–2.10]/77

1.5 [1.20–2.10]/31

0.60

1.85

1.88

0.91

  1. Maximum or minimum values during the period of HFNO. Categorical variables are expressed as proportion, and continuous variables as median (IQR) for original-eligible population and percentage and mean for weighted population
  2. HFNO high-flow nasal oxygen therapy, SpO2 peripheral oxyhemoglobin saturation, SOFA Sequential Organ Failure Assessment, RCP C-reactive protein, IL interleukin, LDH lactate dehydrogenase, GPT glutamate pyruvate transaminase
Back to article page

Critical Care

ISSN: 1364-8535